FDA suspends use of Trasylol due to potential drug injury
May 20, 2008
The FDA reports that it has suspended the use of Trasylol, a drug used to control bleeding during heart surgery, due to the increased risk for potential drug injury.
The suspension of Trasylol comes after a study revealed in November showed that Trasylol had an increased risk of drug injuries, including death, for patients during heart surgery than other antifibrinolyitc drugs.
The FDA will set forth a protocol that will still allow use of Trasylol, despite its risk for drug injury, for patients who have increased risk of blood loss and transfusion during coronary artery bypass graft surgery and who cannot tolerate alternative drugs.
However, the drug with increased risk for drug injury, including death, will be not be used otherwise.
Trasylol could be responsible for Texas drug injuries during heart surgery.